Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Latozinemab - Alector

Next Previous
Drug Profile

Latozinemab - Alector

Alternative Names: AL-001; GSK-4527223

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adimab; Alector
  • Developer Alector; GSK
  • Class Antidementias; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Recombinant proteins
  • Mechanism of Action Sortilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Frontotemporal dementia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis; Frontotemporal dementia

Most Recent Events

  • 31 Dec 2024 Latozinemab - Alector receives Orphan Drug status for Frontotemporal dementia in European Union
  • 05 Jun 2024 Alector completes the phase-II INFRONT-2 trial in Frontotemporal dementia in the UK, Germany, Italy, Netherland, Canada and USA (NCT03987295)
  • 07 Feb 2024 Latozinemab - Alector receives Breakthrough Therapy status for Frontotemporal dementia in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top